Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ganitumab + mFOLFIRINOX in Metastatic Pancreatic Cancer
NCT01473303Phase 2Withdrawn
- Sponsor
- Cancer and Leukemia Group B
- Start
- Aug 2012
- Primary completion
- Aug 2012
- Modality
- Monoclonal Antibodies
01
Overview
A Phase 2 trial of ganitumab in pancreatic ductal adenocarcinoma (PDAC), sponsored by Cancer and Leukemia Group B. Planned start Aug 2012; status: withdrawn.
02
Drugs
ganitumab
03
Conditions
pancreatic ductal adenocarcinoma (PDAC)
Beyond the preview
Go deeper on NCT01473303.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01473303.